Pharma

Your Article Summary

See Latest Articles

Large, long-term study shows Avandia has no increased overall cardiovascular risk compared to other commonly used diabetes medicines
GlaxoSmithKline, 06/08/09

Clinical trial results presented today at the American Diabetes Association annual meeting show that overall rates of cardiovascular hospitalization and cardiovascular death are similar in patients taking Avandia (rosiglitazone) compared to those receiving metformin and sulfonylurea.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09

Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/17/09

Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09

 See all of Drug Trials